Jubilant Pharmova : Investor Presentation February 2022

Investor Presentation

February 2022

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and

objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

2

Jubilant Pharmova Limited - Overview

	Jubilant Pharmova Limited	Jubilant Life
		Sciences Limited
		renamed as
100%		Jubilant Pharmova
	Limited on Feb 1,
	Jubilant Pharma Limited
	2021. Company
		continues to remain
100%		listed on NSE & BSE
	Jubilant Biosys Limited
100%
	Jubilant Therapeutics India Limited

	FY21 Revenue Split (Continuing Business)
	Segment Wise		Region Wise
	CRDS		China and ROW	India
	7%	5%
	5%
	Specialty		Europe & Japan
	Pharmaceutical	8%
Generics	s
24%	38%

CDMO	USA & Canada
80%
33%

Business Structure

Key Highlights

Jubilant Pharma (Pharmaceuticals)

Specialty Pharmaceuticals

• Radiopharma
• Allergy Immunotherapy

CDMO

• CMO of Sterile Injectable and Non Sterile Products
• Active Pharmaceutical Ingredients

Generics

• Dosage Formulations

Jubilant Biosys

Contract Research

and Development

Services

Jubilant

Therapeutics

Proprietary Novel

Drugs

• US$ 820 million integrated global pharmaceuticals, and contract research company
• Strong position in Specialty Pharmaceuticals - radiopharmaceuticals, allergy immunotherapy and CMO of Sterile Injectables & Non-Sterile products
• One of the leading India based Contract research and development companies
• Proprietary business has strong portfolio of programs in the areas of oncology and auto immune disorders
• 6 manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Jubilant Biosys Limited provides contract research and development services through 2 world class research centers in Bangalore and Noida in India.
• Employs ~6,100 people globally, including over 2,300 in North America

3

Jubilant Pharmova - Business Snapshot

Pharmaceuticals

1			Specialty Pharmaceuticals
		 #3 radiopharmaceutical manufacturer in the US
	Radio			 Manufacturing facility based in Montreal Canada
	pharma			 # 2 commercial radiopharmacy network in the US with 48
				radiopharmacies spread across 22 states in the US
2
		 #2 player in the allergenic extract market in the US
	Allergy
			 Sole supplier of venom in the US
	Immuno-
	therapy			 Manufacturing facility at Spokane, Washington, USA

Contract Research and Development Services

• Fully integrated Drug Discovery services provider
• Facilities in Noida and Bangalore
• Provides Drug Discovery services to global innovators with focus on US, EU and Japan.

Proprietary Novel Drugs

 Developing first-in-class and best in class programs in the area of oncology and

autoimmune disorders

1

CMO

2

API

1

Dosage Formulations

CDMO

• Fully integrated leading contract manufacturer
• Integrated with Radiopharma business as supplier of cold kits
• Manufacturing facilities in Spokane, US and Montreal, Canada
• Manufacturing facility at Nanjangud, India
• ~60% of API sales are to regulated markets
• Leading market share in key products in the US

Generics

• Manufacturing facilities at Roorkee, India and Salisbury, US
• Market leadership in select key products in the US
• Vertical integration into API business

 Lead program LSD1/HDAC6 inhibitor has successfully received FDA clearance for IND

filing and is on track for initiation of Phase 1 trials in Q4' FY22.

 IND filings for other pipeline programs are expected to follow in FY23.

High-Quality,World-Class, Low Cost Manufacturing Footprint and Operational Facilities

Spokane, Washington, USA

• Contract manufacturing of Sterile injectable and Allergy therapy

Salisbury, Maryland, USA

• Solid Dosage Formulations (Tablets & Capsules)

Facility	Last Inspection
Montreal, Radiopharma	Sep, 2017
Montreal, CMO	May, 2018
Nanjangud	Dec, 2018

Montreal, Canada

 Contract Manufacturing of

Sterile Injectables and non-

Sterile Products

Montreal, Canada

 Radiopharmaceuticals

Pharmaceuticals Manufacturing Facilities

Biosys Facilities

Biosys Gr. Noida

Facility

Roorkee, Uttarakhand

• Generics manufacturing

Noida

Corporate Office

Nanjangud, Karnataka

 API manufacturing

Biosys Bangalore

Facility

Salisbury	Feb, 2020
Roorkee	Mar, 2021
Spokane	Aug, 2021

6 manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Jubilant Biosys Limited provides contract research and development services through 2 world class research centers in Bangalore and Noida in India.

5